Nuclear Medicine Communications最新文献

{"title":"Study on the correlation between IDH gene mutation status in gliomas and metabolic parameters in 18F-FDG PET/CT.","authors":"Lei Zeng, Ling Jiang, Tieying Ning, Yuanyuan Zhao, Yongyi Zhang, Junchen Zhang","doi":"10.1097/MNM.0000000000002215","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002215","url":null,"abstract":"<p><strong>Aim: </strong>To explore the correlation between isocitrate dehydrogenase (IDH) mutation status and 18F-deoxyglucose (18F-FDG) PET/computed tomography (CT) metabolic parameters in gliomas, and screen imaging biomarkers for preoperative prediction of IDH genotype.</p><p><strong>Methods: </strong>Clinical and preoperative PET/CT data of 85 pathologically confirmed glioma patients were retrospectively analyzed, including 34 IDH-mutant and 51 IDH-wild-type cases. Lesion maximum standard uptake value (SUVmax), SUVmax T/C (lesion-to-contralateral cortex) and SUVmax T/W (lesion-to-contralateral white matter) were measured. Intergroup differences were compared via one-way analysis of variance, and receiver operating characteristic curves were applied to assess the predictive efficacy of significant parameters.</p><p><strong>Results: </strong>All three metabolic indices were markedly elevated in IDH-wild-type tumors: SUVmax (11.77 ± 5.94 vs. 9.46 ± 3.30; P = 0.042), SUVmax T/C (1.63 ± 0.67 vs. 1.34 ± 0.40; P = 0.028), SUVmax T/W (2.80 ± 1.19 vs. 2.31 ± 0.63; P = 0.024). SUVmax T/C [area under the curve (AUC) = 0.671] and SUVmax T/W (AUC = 0.668) showed moderate predictive value, whereas SUVmax had poor performance (AUC = 0.339). Patients with IDH mutation were significantly younger.</p><p><strong>Conclusion: </strong>IDH-wild-type gliomas present stronger glycolytic metabolism. 18F-FDG PET/CT-derived SUVmax, SUVmax T/C, and SUVmax T/W allow noninvasive preoperative evaluation of IDH status, with normalized ratio parameters demonstrating better diagnostic stability. Higher metabolic heterogeneity exists in IDH-wild-type gliomas.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148679333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current UK practice in [ 177 Lu]-DOTATATE peptide receptor radionuclide therapy: a national survey of national health service centres.","authors":"Kate Houghton, Frederick Varley, Ella Cook, Emma Norman, Daniela Panciera, Daniel Sinclair, Anne-Marie Stapleton","doi":"10.1097/MNM.0000000000002154","DOIUrl":"10.1097/MNM.0000000000002154","url":null,"abstract":"<p><strong>Objectives: </strong>With increasing use of [ 177 Lu]-DOTATATE peptide receptor radionuclide therapy (PRRT) across the UK, variation in clinical and practical delivery aspects is likely to exist between centres. The aim of this study was to capture current practice in the UK by surveying administration methodologies, imaging and dosimetry protocols, discharge restrictions, workforce and task duration, and treatment-related incidents.</p><p><strong>Methods: </strong>A web-based survey with 54 questions was used to investigate PRRT therapy practice. The survey included multiple-choice and free-text questions and was distributed to UK National Health Service centres via professional mailing lists and direct contact. Responses were reviewed and interpreted by a panel of nuclear medicine physicists.</p><p><strong>Results: </strong>Twenty responses were received from National Health Service centres, representing 20/24 UK sites delivering [ 177 Lu]-DOTATATE therapy. Inter-centre variation was observed in administration methods, imaging schedules, dosimetry practice, and discharge restrictions for radiation safety. Most centres (15/20) do not routinely perform dosimetry imaging, primarily due to imaging time and staffing constraints, and lack of interest due to limited perceived clinical benefit. Approximately 59 treatment-related incidents were reported over a 21-month period; contamination and human error were cited as the most common causes.</p><p><strong>Conclusion: </strong>This survey demonstrates variation in the practical aspects and implementation of [ 177 Lu]-DOTATATE therapy in the UK. Variability in behavioural restrictions highlights the need for clear national guidance on performing risk assessments for PRRT, to ensure a consistent patient experience. Free-text responses, particularly those relating to administration methods and incident learning, demonstrate the range of experiences across centres and the potential value of shared learning.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"928-937"},"PeriodicalIF":1.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147675581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18 F choline PET/MR to assess clinically significant disease in prostate cancer: Correlation with maximum and total cancer core length obtained via template mapping biopsies.","authors":"Athar Haroon, Ahmad Almuhaideb, Sola Adeleke, Laura May Davis, Raymond Endozo, Rayjanah Allie, Asim Afaq, Ghulam Mustafa Shah Syed, Soleen Ghafoor, Mark Emberton, Jamshed Bomanji","doi":"10.1097/MNM.0000000000002158","DOIUrl":"10.1097/MNM.0000000000002158","url":null,"abstract":"<p><strong>Objective: </strong>To assess the accuracy of 18 F choline PET/magnetic resonance (MR) when compared with the reference standard MRI-guided template mapping (TPM) biopsies for evaluation of biochemical relapse of prostate cancer in patients with clinically significant and insignificant disease.</p><p><strong>Material and methods: </strong>A total of 26 prostate lobes in 13 patients with rise in prostate-specific antigen (PSA), age range 56-79; median 66 years, who had 18 F choline PET/MR and underwent TPM. Whole body PET/MR images were correlated with maximum cancer core length (MCCL) and total cancer core length (TCCL) obtained via TPM.</p><p><strong>Results: </strong>The mean age of the patients was 66 years (median: 66, range: 56-79 years), and the mean PSA level was 5.17 ng/ml (median: 4.40 ng/ml, range: 1.0-11.1 ng/ml; Roche Modular method). The mean maximum standard uptake value (SUV max ) was 3.18 (median: 2.3, range: 0.6-12.3). The mean MCCL was 1.5 mm (range: 1-9 mm), mean TCCL was 3.1 mm (range: 1-28 mm). We evaluated the correlation ( P value) between MCCL, TCCL, and SUV max on 18 F choline PET/MR with univariate analysis. P value for MCCL was 0.078 and for TCCL 0.093. Overall, the sensitivity, specificity, positive predictive value, negative predictive value, and area under the curve were 77, 70, 58, 85, and 0.621 (95% confidence interval: 2.16-4.19).</p><p><strong>Conclusion: </strong>18 F choline PET/MR allows detection of clinically significant and insignificant prostate cancer. Multiple previous treatments can give false positive results. False negative results with 18 F choline PET/MR can be because of very small volume (≤2 mm) disease.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"994-1006"},"PeriodicalIF":1.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of preoperative gallium-68 prostate-specific membrane antigen PET/computed tomography in predicting biochemical recurrence after radical prostatectomy.","authors":"Hüseyin Mert Durak, Adem Sanci, Emre Hepşen, Metin Yiğman, Alev Çinar, Azmi Levent Sağnak, Ahmet Nihat Karakoyunlu","doi":"10.1097/MNM.0000000000002149","DOIUrl":"10.1097/MNM.0000000000002149","url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluated the prognostic value of intraprostatic maximum standardized uptake value (SUV max ) on primary-staging gallium-68 prostate-specific membrane antigen ( 68 Ga-PSMA) PET/computed tomography for predicting biochemical recurrence (BCR) and BCR-free survival after margin-negative radical prostatectomy, and explored an SUV max cutoff.</p><p><strong>Methods: </strong>This retrospective study included 78 men (2023-2024) who underwent preoperative 68 Ga-PSMA PET/computed tomography, all reevaluated by an experienced nuclear medicine physician. BCR was defined as prostate-specific antigen at least 0.2 ng/ml on two consecutive tests. Follow up duration and time to recurrence were recorded. Mann-Whitney U, χ 2 , receiver operating characteristic, Kaplan-Meier, and Cox regression analyses were performed.</p><p><strong>Results: </strong>BCR occurred in 21 of 78 patients (26.9%). Median follow up was 18 months, and median time to BCR was 12 months. Intraprostatic SUV max was significantly higher in patients with BCR ( P  < 0.001). Receiver operating characteristic analysis showed an area under the curve of 0.798; the exploratory cutoff was 12.8, with 71.4% sensitivity and 84.2% specificity. Kaplan-Meier analysis showed significantly worse BCR-free survival in patients with SUV max at least 12.8 (log-rank P  < 0.001). In univariable Cox analysis, each 1-unit increase in SUV max was associated with higher BCR risk (hazard ratio = 1.11, 95% confidence interval 1.06-1.16, P  < 0.001), and this association remained significant in limited multivariable models.</p><p><strong>Conclusions: </strong>Intraprostatic SUV max appears to be an exploratory imaging biomarker associated with postoperative BCR and shorter BCR-free survival rather than a stand-alone prognostic determinant. Larger prospective multicenter studies are needed for validation.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"959-965"},"PeriodicalIF":1.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147628219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visualizing the metabolic battleground: the role of PET imaging in understanding immunometabolism and the tumor microenvironment.","authors":"Raydel Briankwee Amalo, Hendra Budiawan, Budi Darmawan","doi":"10.1097/MNM.0000000000002150","DOIUrl":"10.1097/MNM.0000000000002150","url":null,"abstract":"<p><p>PET has evolved beyond tumor glucose metabolism imaging to assess the immunometabolic landscape of the tumor microenvironment (TME) and systemic immune responses. Immunometabolism, encompassing glycolysis, oxidative phosphorylation, and fatty acid oxidation, governs immune cell activation, differentiation, and effector function, shaping antitumor immunity and immunotherapy outcomes. PET radiotracers, including fluorine 18-fluorodeoxyglucose, amino acid/nucleoside tracers ( 11 C-methionine, 18 F-F-AraG), cytokine/receptor-targeted tracers ( 64 Cu-IFNγ, 68 Ga-NOTA-Nb109), and macrophage-directed tracers ( 11 C-PK11195, gallium-68-labeled NOTA-mannosylated serum albumin), enable noninvasive visualization of immune metabolism, proliferation, and polarization. Novel agents such as gallium-68-labeled fibroblast activation protein inhibitor and 68 Ga-Pentixafor further capture stromal remodeling and immune cell recruitment. Clinically, immunometabolic PET guides oncology, immunotherapy, autoimmune, inflammatory, and infectious disease management by distinguishing immune activation from tumor progression, evaluating therapeutic response, and identifying active inflammation. This emerging imaging paradigm provides mechanistic insights into immune-tumor interactions and offers a precision tool for personalized treatment strategies.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"905-916"},"PeriodicalIF":1.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment and validation of a nomogram model for poorly differentiated thyroid cancer based on the Surveillance, Epidemiology, and End Result database.","authors":"Jing Liang, Yingying Yang, Ru Mi, Wei Zheng, Qiang Jia, Jian Tan, Ning Li, Zhaowei Meng","doi":"10.1097/MNM.0000000000002163","DOIUrl":"10.1097/MNM.0000000000002163","url":null,"abstract":"<p><strong>Purpose: </strong>To retrospectively analyze the clinicopathological characteristics and prognosis-related factors of poorly differentiated thyroid cancer (PDTC), construct a nomogram model, and predict the 3-, 5-, and 10-year overall survival (OS) and cancer-specific survival (CSS).</p><p><strong>Methods: </strong>PDTC patients between 1975 and 2020 from the Surveillance, Epidemiology, and End Result Program were divided into training (70%) and validation (30%) sets. Univariate and multivariate Cox regression analyses identified independent prognostic factors for PDTC, and a nomogram prognostic model was constructed. The predictive ability of the model was assessed using the receiver operating characteristic curve, decision curve analysis, and calibration curve.</p><p><strong>Results: </strong>A total of 983 PDTC patients were enrolled. Univariate and multivariate Cox regression analyses showed that age, gender, malignant tumor behavior, time from diagnosis to treatment, tumor size, treatment modality, N and M stages were independent prognostic factors for OS. For CSS, age, malignant tumor behavior, time from diagnosis to treatment, treatment modality, regional nodes examined, N and M stages were identified as independent prognostic factors. The nomogram model constructed based on these factors exhibited good predictive ability, clinical applicability, and calibration accuracy.</p><p><strong>Conclusion: </strong>The nomogram model constructed based on clinicopathological characteristics such as age, gender, malignant tumor behavior, time from diagnosis to treatment, tumor size, treatment modality, N and M stages can effectively predict the OS of PDTC patients. Age, malignant tumor behavior, time from diagnosis to treatment, treatment modality, regional nodes examined, N and M stages can effectively predict the CSS.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"938-950"},"PeriodicalIF":1.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147729609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Added value of maximum standardized uptake value and diffusion-weighted imaging in s taging of high risk breast cancer patients using simultaneous 18 F-flurodeoxyglucose positron emission tomography and magnetic resonance imaging.","authors":"Padma Subramanyam, Shanmuga Sundaram Palaniswamy, Sibiraj Hemant Patel","doi":"10.1097/MNM.0000000000002156","DOIUrl":"10.1097/MNM.0000000000002156","url":null,"abstract":"<p><strong>Background: </strong>Accurate staging is essential in high risk breast cancer to guide management. While flurodeoxyglucose (FDG) PETCT is well established, limited data exist on the cancers role of maximum standardized uptake value (SUV max ) and diffusion-weighted imaging (DWI), especially with limited access to positron emission tomography and magnetic resonance imaging (PETMR). This study evaluates the diagnostic performance of PETMR and correlation between SUV max and apparent diffusion coefficient (ADC) values in staging these patients.</p><p><strong>Methods: </strong>This retrospective study includes 76 biopsy-confirmed treatment-naïve high risk breast cancer patients (triple negative breast cancer and non-triple negative breast cancer) who underwent FDG PETMR (2021-2024). A total of 965 lesions were analysed. Lesion detection, quantitative parameters, and diagnostic performance were assessed, including receiver operating characteristic analysis of SUV-ADC biomarkers.</p><p><strong>Results: </strong>SUV max showed an inverse correlation with ADC mean ( r  = -0.41) and ADC min ( r  = -0.47), strongest in primary breast tumours and skeletal metastases. The SUV max /ADC min ratio effectively graded tumours and correlated with Ki-67 ( r  = 0.55). FDG PET demonstrated higher specificity (87.8%) than DWI (82.7%), while DWI was more sensitive for detecting small lesions. False positives and false-negative lesions were identified by correlating PET and DWI findings with histopathology (wherever available) or using follow up imaging.</p><p><strong>Conclusion: </strong>Simultaneous PETMR is promising for accurate staging of high risk breast cancer. PET demonstrates higher specificity, whereas DWI improves sensitivity for detecting smaller lesions, particularly in liver, brain, and lungs. A combined FDG PET DWI approach enhances overall diagnostic accuracy and improves lesion characterization and staging. Additionally, the combination of SUV max and Ki-67 provides a reliable indicator of tumour aggressiveness.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"975-985"},"PeriodicalIF":1.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative [ 18 F]-fluorodeoxyglucose PET analysis with a Gaussian normative template.","authors":"Zhilin Qian, Bomeng Du, Fang Wan, Mingzhu Zheng, Yiwei Chen, Shangwen Jin, Jixia Wei, Yaying Li, Xiaoxiao Wang","doi":"10.1097/MNM.0000000000002155","DOIUrl":"10.1097/MNM.0000000000002155","url":null,"abstract":"<p><strong>Objective: </strong>To develop a standardized quantitative [ 18 F]-fluorodeoxyglucose (FDG) PET normative template and evaluate its clinical utility for objective epileptogenic focus localization in drug-resistant epilepsy.</p><p><strong>Methods: </strong>[ 18 F]-FDG PET data from 89 participants across three multicenter datasets were harmonized and categorized into: a construction group ( n = 55 healthy subjects), an independent specificity validation group ( n = 10 healthy subjects), and a clinical detection group ( n = 24 temporal lobe epilepsy [TLE] patients). After spatial and intensity normalization, four candidate models (Gaussian, Gamma, Smoothed Gaussian, and Smoothed Gamma) were constructed. Normality was validated via voxel-wise pass rates to select the optimal template, with clinical utility assessed using a z -score threshold of less than -3.5.</p><p><strong>Results: </strong>The Smoothed Gaussian model exhibited the highest voxel pass rate and was established as the final template. Validation in the 10 independent healthy subjects yielded no false positives, confirming high specificity. Furthermore, the template accurately identified metabolic abnormalities in all 24 TLE patients, consistent with clinically confirmed foci.</p><p><strong>Conclusion: </strong>The Smoothed Gaussian-derived template enables objective and reproducible [ 18 F]-FDG PET analysis. It significantly improves focus localization accuracy and provides a reliable quantitative tool for guiding drug-resistant epilepsy surgery.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"966-974"},"PeriodicalIF":1.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147628284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic high ratio on whole-body radioiodine scans: a robust prognostic marker in well differentiated thyroid cancer.","authors":"Prakash Singh, Prasanta K Pradhan, Manish Ora, Vineet Mishra, Yogita Khandelwal, Bela Jain","doi":"10.1097/MNM.0000000000002159","DOIUrl":"10.1097/MNM.0000000000002159","url":null,"abstract":"<p><strong>Purpose: </strong>Radioiodine therapy (RIT) is a well established adjuvant therapy in intermediate and high-risk patients of well differentiated thyroid cancer (WDTC). Diagnostic whole-body radioiodine (WBRI) scans are done to evaluate remnant lesions and metastatic burden. Sometimes, diffuse liver uptake is noted in WBRI scans, even in the absence of liver metastasis. Few studies have assessed the hepatic-thigh ratio (HTR) on WBRI and found its correlation with the functional status of tumour cells and prognostication. We assessed the baseline HTR in WDTC and evaluated the dynamics of HTR in different groups after RIT in the follow-up.</p><p><strong>Methods: </strong>Sixty WDTC patients (30 in metastatic and 30 in nonmetastatic groups) were included in a prospective study. Patients underwent baseline WBRI scans, and RIT was done. Follow-up was conducted at six and 12 months, including biochemical investigations and WBRI. The baseline hepatic-to-thigh ratio (HTR0) was calculated as the average counts per pixel of a region of interest drawn in the right lobe of the liver and the mid-thigh. Correlation analysis of HTR0 and follow-up HTR (HTR1 and HTR2) with tumour markers, liver enzymes, histopathology, and outcome was done.</p><p><strong>Results: </strong>The mean ages of patients with and without metastasis were 35.8 and 42.03 years, respectively. There was no significant difference between serum thyroglobulin, serum thyroglobulin antibody (TgAb), age, thyroid-stimulating hormone, and HTR0, HTR1, and HTR2 among nonmetastasis and metastasis groups ( P  > 0.05). Papillary and follicular carcinomas were noted in 46 and 14, respectively. A complete response was noted in the 31 patients and was associated with the papillary carcinoma and HTR2 < 2.135. HTR2 < 2.135 predicted a complete response with a sensitivity and specificity of 90% and 82%, respectively. Rising HTR in follow-up was associated with incomplete response. HTR1 and HTR2 were higher in follicular carcinoma compared to papillary carcinoma.</p><p><strong>Conclusion: </strong>HTR0 is unrelated to the disease burden (thyroglobulin and metastasis) and histopathological variant. High HTR0 is associated with poor response and residual disease. Rising HTR in follow-up also signifies the inadequate response to RIT. HTR acts as a supplementary tool to existing risk factors, and thyroglobulin for predicting therapeutic response in DTC.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"951-958"},"PeriodicalIF":1.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot feasibility study investigating 68 Ga-NODAGA-RGD PET-computed tomography molecular angiogenesis imaging in patients with peripheral arterial diseases: can it be of potential clinical value?","authors":"Vishwajeet Jadhav, Priyanka Verma, Ashok Chandak, Pravin Shinde, Dev Adhikari, Sandip Basu","doi":"10.1097/MNM.0000000000002160","DOIUrl":"10.1097/MNM.0000000000002160","url":null,"abstract":"<p><strong>Introduction: </strong>Peripheral arterial disease (PAD) is a common vascular condition caused mainly by atherosclerosis that can cause ischemia and increase cardiovascular risk. Noninvasive imaging, such as Doppler ultrasonography, provides hemodynamic information but lack molecular insight. Integrin αvβ3 expression reflects angiogenesis in ischemic tissue and radiolabeled RGD peptides can be used to visualize this process noninvasively. This study prospectively assessed the diagnostic performance of 68 Ga-NODAGA-RGD PET-computed tomography (CT) in patients with suspected or proven PAD and correlate the findings to clinical and Doppler findings.</p><p><strong>Materials and methods: </strong>Thirty patients aged 26-87 years (23 males and 7 females, median age 52 years) presented with clinical or Doppler findings that were consistent with PAD underwent an imaging study with 68 Ga-NODAGA-RGD PET-CT 60 ± 15 min following the injection of a radiotracer dose of 3-5 mCi. Tracer uptake was visually rated on a four-point scale relative to liver and spleen activity and the maximum standardized uptake (SUV max ) was documented. Using the clinical and Doppler findings as gold standard diagnostic indices were calculated. An agreement analysis was performed using Cohen's κ and McNemar's test.</p><p><strong>Results: </strong>Fifteen patients had PAD and 15 had non-PAD (tumor-induced thrombosis - 1, cellulitis - 9, diabetic foot - 3, arthritis - 2). 68 Ga-NODAGA-RGD PET-CT was positive in 11 of 15 PAD patients (true positives) and negative in 15 of the 15 non-PAD patients (true negatives), with zero false positives and four false negatives. The sensitivity, specificity, and positive predictive values were 73.34%, 100%, and 100%, respectively. False negatives were primarily associated with acute ischemia lacking angiogenesis.</p><p><strong>Conclusion: </strong>68 Ga-NODAGA-RGD PET-CT shows potential value and agreement with Doppler and clinical assessment for detecting PAD and may serve as a potential molecular imaging modality to evaluate angiogenesis and the disease extent as a complementary diagnostic imaging modality. Although RGD tracers have been explored for theranostic applications in oncology, the uptake levels observed in PAD in this study were generally low and currently do not support such applications. It also provides an evaluation of systemic vascularity outside of localized segments. Larger studies are warranted to validate its disease management implications.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"986-993"},"PeriodicalIF":1.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147646057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}